Current Edition

Ensuring Patient Safety and Cardiovascular Clinical Trial Integrity during a Globa Pandemic

The susceptibility to and the outcomes of COVID-19 are strongly associated with the presence of CV risk factors and with established CV disease. Clinical trials investigating new CV interventions often recruit participants in hospitals, emergency departments or during outpatient interventions or assessments. Jack Martin and Deirdre Albertson at ICON analyse how to ensure patient safety and cardiovascular clinical trial integrity during a global pandemic.